Videos

In part 2 of this 4-part series, Ravi D. Chauhan, MD, FACS, and R. Jonathan Henderson, MD, examine how collaboration among urologists and pathologists, along with renewed attention to bladder mapping techniques, may improve CIS detection in NMIBC.

In this opening segment, Ravi D. Chauhan, MD, FACS, and R. Jonathan Henderson, MD, discuss how underreporting of CIS in pathology reports may limit access to guideline-supported therapies for patients with NMIBC.

Adam B. Weiner, MD, is joined by Nikita R. Bhatt, MBBS, MCh, MMed, FRCS, to discuss the WASHOUT study, a prospective international collaboration examining outcomes among patients admitted with emergency hematuria.

In this closing segment, Dr. Charles J. Ryan leads a discussion on how clinicians integrate multiple sources of evidence when making long term treatment decisions in metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan invites the panel to discuss how clinicians evaluate evidence from observational studies and propensity matched analyses in metastatic castration sensitive prostate cancer (mCSPC).

Charles R. Powell, MD, highlights 12-month data on the Neuspera System for urge urinary incontinence, reflecting on ideal candidates and the treatment's role alongside other SNM options.

PSMA PET improves staging in advanced and recurrent prostate cancer, guiding shared decisions with expert interpretation and paving the way for theranostics.

New ASCO GU data compares fluorinated PSMA PET tracers, showing how bladder activity affects detection of prostate cancer recurrence at low PSA.

Martin Gleave, MD, FRCSC, FACS, explains how the adaptive, biomarker-driven GUNS trial uses neoadjuvant therapy to link genomic subtypes with treatment response.

Advances in laser technology, morcellator design, and anesthetic approach have substantially improved HoLEP efficiency and patient recovery over the past decade, while surgeon-owned procedural checklists and pre-morcellation hemostasis remain the most critical safety practices for avoiding morcellator injury.

This video provides comprehensive review of current minimally invasive BPH therapies, focusing on safety, patient experience, and key distinctions between procedural categories.

Jennifer U. Miles-Thomas, MD, MBA, reflects on the key pillars to building successful surgeon/advanced practice providers partnerships.

In the FIT-001 trial, the combination of darlifarnib and cabozantinib demonstrated promising early antitumor activity in patients with ccRCC who had previously progressed on cabozantinib.

This episode explores how long-term management of metastatic castration-sensitive prostate cancer is increasingly shaped by personalized treatment planning that balances disease burden, patient fitness, quality of life, and shared decision-making.

This series explores how fatigue and other treatment-related adverse events influence quality of life and treatment persistence in metastatic castration-sensitive prostate cancer, with a focus on practical strategies for assessment, management, and supportive care in patients receiving ADT and ARPI-based therapy.

Song Jiang, MD, discusses evolving biomarker approaches that may redefine care in NMIBC.

Song Jiang, MD, PhD, discusses the balance between efficacy and safety data when considering the role for BCG/ICI combinations in BCG-naive NMIBC.

Charles R. Powell, MD, discusses how the rise of GLP-1–associated weight loss may influence outcomes and device management in sacral neuromodulation.

In this segment, Dr. Charles J. Ryan presents a clinical case scenario to explore how real world evidence informs treatment decisions in metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan and the panel explore how clinicians interpret subgroup analyses, pivotal trial data, and real world evidence when managing metastatic castration sensitive prostate cancer (mCSPC).

Akanksha Mehta, MD, MS, discusses why the updated vasectomy guideline expands its focus on fertility restoration, emphasizing patient counseling on reversal and individualized decision-making for future family building.

Adanma Ayanambakkam, MD, MS, discusses the FIT-001 trial and early findings on the safety profile for darlifarnib plus cabozantinib in ccRCC.

Real-world PSMA PET in prostate cancer reveals reporting variability, limits at low PSA, and mixed FDG PET value—what clinicians learn in practice.

PSMA PET interpretation standards evolve, with SUV reporting and staging differences across settings shaping therapy choices, sequencing, and metastasis-directed radiation decisions.

Helen L. Bernie, DO, MPH, discusses how expanded TRT labeling could improve care for men with idiopathic hypogonadism.

Nannan Thirumavalavan, MD, reflects on how the FDA’s testosterone labeling changes, informed by the TRAVERSE trial, have influenced TRT prescribing and clinician confidence over the past year.

Daniel J. George, MD, highlights survey findings on the role of caregivers in the treatment journey for patients with metastatic prostate cancer.

In this video, Dalia Kaakour, MD, MPH, highlights retrospective findings on the use of ctDNA in detecting residual disease and recurrence in testicular cancer.

In this video, Meri-Margaret Deoudes discusses ongoing challenges for patients with bladder cancer, including costs of care, delayed diagnoses among women, and access barriers among patients in rural areas.

PSMA PET scans reshape prostate cancer care—learn who should interpret results, how reports vary, and why a team approach guides treatment.